Screener
Apogee Therapeutics, Inc. APGE Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDED MARCH 31, 2026 | THREE MONTHS ENDED MARCH 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(74,111) | $(55,339) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation expense | 408 | 207 |
| Equity-based compensation expense | 17,155 | 11,126 |
| Amortization of discounts on marketable securities | (1,549) | (2,379) |
| Non-cash lease expense | 980 | 857 |
| Changes in operating assets and liabilities: |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s net income?
- Apogee Therapeutics, Inc. (APGE) reported net income of -$74.11M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s net income changed year-over-year?
- Apogee Therapeutics, Inc.'s net income decreased by 33.9% year-over-year, from -$55.34M to -$74.11M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s net income?
- Over 3 years (2022 to 2025), Apogee Therapeutics, Inc.'s net income has grown at a 49.9% compound annual growth rate (CAGR), from -$75.99M to -$255.84M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Apogee Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude